(Q33777244)

29 July 2017

1 reference

title

Evolution, mechanisms, and classification of antiarrhythmic drugs: focus on class III actions (English)

1 reference

29 July 2017

Nattel S

1

1 reference

29 July 2017

Singh BN

series ordinal

2

1 reference

29 July 2017

language of work or name

English

0 references

publication date

1 November 1999

1 reference

American Journal of Cardiology

29 July 2017

published in

1 reference

29 July 2017

volume

84

1 reference

29 July 2017

issue

9A

1 reference

29 July 2017

page(s)

11R-19R

1 reference

Ventricular fibrillation precipitated by cardiac catheterization; complete recovery of the patient after 45 minutes

29 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2900697-9

Effect of Lidocaine on Ventricular Arrhythmias in Patients with Coronary Heart Disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2900697-9

The coronary care unit. New perspectives and directions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2900697-9

Lidocaine in the prevention of primary ventricular fibrillation. A double-blind, randomized study of 212 consecutive patients.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2900697-9

Intramuscular lidocaine for prevention of lethal arrhythmias in the prehospitalization phase of acute myocardial infarction.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2900697-9

Effects of prophylactic lidocaine in suspected acute myocardial infarction. An overview of results from the randomized, controlled trials

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2900697-9

Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2900697-9

International mexiletine and placebo antiarrhythmic coronary trial: I. Report on arrhythmia and other findings. Impact Research Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2900697-9

Effect of the antiarrhythmic agent moricizine on survival after myocardial infarction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2900697-9

Effects of prophylactic antiarrhythmic drug therapy in acute myocardial infarction. An overview of results from randomized controlled trials

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2900697-9

Current antiarrhythmic drugs: an overview of mechanisms of action and potential clinical utility

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2900697-9

The coming of age of the class III antiarrhythmic principle: retrospective and future trends

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2900697-9

From first class to third class: recent upheaval in antiarrhythmic therapy--lessons from clinical trials

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2900697-9

A third class of anti-arrhythmic action. Effects on atrial and ventricular intracellular potentials, and other pharmacological actions on cardiac muscle, of MJ 1999 and AH 3474

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2900697-9

Efficacy and safety of quinidine therapy for maintenance of sinus rhythm after cardioversion. A meta-analysis of randomized control trials.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2900697-9

Antiarrhythmic drug therapy and cardiac mortality in atrial fibrillation. The Stroke Prevention in Atrial Fibrillation Investigators

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2900697-9

Newer developments in the management of atrial fibrillation.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2900697-9

A fourth class of anti-dysrhythmic action? Effect of verapamil on ouabain toxicity, on atrial and ventricular intracellular potentials, and on other features of cardiac function

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2900697-9

Comparative mechanisms of action of antiarrhythmic drugs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2900697-9

Effect of Altering Potassium Concentration on the Action of Lidocaine and Diphenylhydantoin on Rabbit Atrial and Ventricular Muscle

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2900697-9

Actions of lidocaine on transmembrane potentials of subendocardial Purkinje fibers surviving in infarcted canine hearts.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2900697-9

Kinetics of onset of rate-dependent effects of Class I antiarrhythmic drugs are important in determining their effects on refractoriness in guinea-pig ventricle, and provide a theoretical basis for their subclassification

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2900697-9

Antiarrhythmic drug classifications. A critical appraisal of their history, present status, and clinical relevance

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2900697-9

Electrophysiologial and beta-receptor blocking effects of MJ 1999 on dog and rabbit cardiac tissue

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2900697-9

The Sicilian gambit. A new approach to the classification of antiarrhythmic drugs based on their actions on arrhythmogenic mechanisms. Task Force of the Working Group on Arrhythmias of the European Society of Cardiology

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2900697-9

Antiarrhythmic drugs: a reorientation in light of recent developments in the control of disorders of rhythm

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2900697-9

Electrophysiological effects of flecainide on anisotropic conduction and reentry in infarcted canine hearts.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2900697-9

Reentrant arrhythmias in the subacute infarction period. The proarrhythmic effect of flecainide acetate on functional reentrant circuits

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2900697-9

Determinants and mechanisms of flecainide-induced promotion of ventricular tachycardia in anesthetized dogs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2900697-9

Risk factors for the development of proarrhythmic events

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2900697-9

Alterations in regional myocardial distribution and arrhythmogenic effects of aprindine produced by coronary artery occlusion in the dog

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2900697-9

Relationship between an arrhythmogenic action of lidocaine and its effects on excitation patterns in acutely ischemic porcine myocardium

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2900697-9

Effect of drugs on conduction delay and incidence of ventricular arrhythmias induced by acute coronary occlusion in dogs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2900697-9

Experimental evidence for proarrhythmic mechanisms of antiarrhythmic drugs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2900697-9

Interaction of ischaemia and encainide/flecainide treatment: a proposed mechanism for the increased mortality in CAST I

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2900697-9

Action potential prolongation and induction of abnormal automaticity by low quinidine concentrations in canine Purkinje fibers. Relationship to potassium and cycle length.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2900697-9

Pharmacological response of quinidine induced early afterdepolarisations in canine cardiac Purkinje fibres: insights into underlying ionic mechanisms.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2900697-9

The electrophysiological mechanism of ventricular arrhythmias in the long QT syndrome. Tridimensional mapping of activation and recovery patterns

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2900697-9

Cellular basis of biventricular hypertrophy and arrhythmogenesis in dogs with chronic complete atrioventricular block and acquired torsade de pointes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2900697-9

Sex difference in risk of torsade de pointes with d,l-sotalol

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2900697-9

Class III antiarrhythmic agents have a lot of potential but a long way to go. Reduced effectiveness and dangers of reverse use dependence

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2900697-9

Comparative mechanisms of antiarrhythmic drug action in experimental atrial fibrillation. Importance of use-dependent effects on refractoriness

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2900697-9

Class III antiarrhythmic drug action in experimental atrial fibrillation. Differences in reverse use dependence and effectiveness between d-sotalol and the new antiarrhythmic drug ambasilide

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2900697-9

Effects of the novel antiarrhythmic agent azimilide on experimental atrial fibrillation and atrial electrophysiologic properties

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2900697-9

Rate-dependent prolongation of cardiac action potentials by a methanesulfonanilide class III antiarrhythmic agent. Specific block of rapidly activating delayed rectifier K+ current by dofetilide

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2900697-9

Sustained depolarization-induced outward current in human atrial myocytes. Evidence for a novel delayed rectifier K+ current similar to Kv1.5 cloned channel currents

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2900697-9

Evidence for two components of delayed rectifier K+ current in human ventricular myocytes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2900697-9

The molecular and ionic specificity of antiarrhythmic drug actions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2900697-9

Antisense oligodeoxynucleotides directed against Kv1.5 mRNA specifically inhibit ultrarapid delayed rectifier K+ current in cultured adult human atrial myocytes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2900697-9

A mechanistic link between an inherited and an acquired cardiac arrhythmia: HERG encodes the IKr potassium channel

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2900697-9

Coassembly of K(V)LQT1 and minK (IsK) proteins to form cardiac I(Ks) potassium channel

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2900697-9

K(V)LQT1 and lsK (minK) proteins associate to form the I(Ks) cardiac potassium current

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2900697-9

What is an antiarrhythmic drug? From clinical trials to fundamental concepts

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2900697-9

Atrial fibrillation begets atrial fibrillation. A study in awake chronically instrumented goats

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2900697-9

Electrical remodeling in atrial fibrillation. Time course and mechanisms

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2900697-9

Verapamil reduces tachycardia-induced electrical remodeling of the atria

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2900697-9

10.1016/S0002-9149(99)00697-9

7 January 2021

Identifiers

DOI

1 reference

29 July 2017

1 reference